Comparative Pharmacology
Head-to-head clinical analysis: VISKEN versus ZIAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VISKEN versus ZIAC.
VISKEN vs ZIAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective beta-adrenergic receptor antagonist; competitively blocks beta1- and beta2-adrenergic receptors, decreasing heart rate, myocardial contractility, and blood pressure.
ZIAC is a combination of bisoprolol, a cardioselective beta1-adrenergic receptor blocker, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing blood volume.
5 mg orally twice daily, titrated to 10-20 mg twice daily based on response.
ZIAC (bisoprolol fumarate/hydrochlorothiazide) 2.5 mg/6.25 mg to 10 mg/6.25 mg orally once daily, titrated at 2-week intervals based on blood pressure response. Maximum dose: 20 mg/12.5 mg per day.
None Documented
None Documented
Terminal elimination half-life: 10-12 hours in healthy adults; prolonged to 20-40 hours in significant renal impairment.
Bisoprolol: 9–12 h (terminal); HCTZ: 6–15 h (terminal); prolonged in renal impairment; steady state by 5 days
Renal (60-70% unchanged) and fecal (30-40% via biliary excretion as metabolites).
Renal: bisoprolol (50% unchanged), HCTZ (≥95% unchanged); biliary/fecal: bisoprolol (≤2%)
Category C
Category C
Beta Blocker
Beta Blocker + Diuretic